Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425476 · ClinicalTrials.gov registry record · Phase 1
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
A Phase 1 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01425476 is a Phase 1 study that has completed, run by Hartford Hospital. The registered enrollment target is 45 participants.
The verdict
NCT01425476, a Phase 1 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG Cholecalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-07 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425476
The ClinicalTrials.gov registry entry for NCT01425476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01425476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425476 about?
NCT01425476 is a clinical study titled "Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors". This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination wit...
What is the current status of trial NCT01425476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01425476?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Cholecalciferol (DRUG).
Who is sponsoring clinical trial NCT01425476?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.